Moreover, the cure rate of children with ALL was approximately 90%,[33,34] while the survival in patients with AML was only 60% to 70% in developed countries.[35–37] These findings suggested that CEBPE polymorphism was only associated with susceptibility to B-cell ALL subtype, which was also supported by the evidence that GSTM1 and XRCC1 Arg399Glnvariants were only associated with ALL but not AML.[38,39] However, in our study, only 4 and 2 studies were eligible for the analysis of T-cell ALL and AML, respectively, which might compromisethe reliability of these findings. This evidence concerns the gene XRCC1 and acute myeloid leukemia.